| --- | --- | --- | --- | |-------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | WHERE TOMORROW LIVES. | | | | | | | | | | Investor Presentation January 2020 | | | | Forward looking statements Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates" and similar expressions) are forward-looking statements. These statements include those ...

OncoCyte Corporation. (NASDAQ:OCX) Q3 2019 Results Earnings Conference Call November 14, 2019 4:30 PM ET Company Participants Bob Yedid - LifeSci Advisors Ronald Andrews - CEO, President Al Parker - Chief Operating Officer Mitchell Levine - CFO Padma Sundar - Senior Vice President of Marketing and Market Access Tony Kalajian - Chief Accounting Officer Conference Call Participants Paul Knight - Janney Montgomery Scott Bill Quirk - Piper Jaffray Thomas Flaten - Lake Street Capital Markets Bruce Jackson - The ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 1-37648 OncoCyte Corporation (Exact name of registrant as specified in its charter) California 27-1041563 (State or ...

OncoCyte Corporation (NASDAQ:OCX) Q2 2019 Results Earnings Conference Call August 14, 2019 4:30 PM ET Company Participants Glenn Garmont - IR, LifeSci Advisors Ronald Andrews - CEO, President Al Parker - Chief Operating Officer Mitchell Levine - CFO Tony Kalajian - Chief Accounting Officer Lyndal Hesterberg - Chief Scientific Officer Conference Call Participants Paul Knight - Janney Montgomery Scott Thomas Flaten - Lake Street Capital Markets Bruce Jackson - The Benchmark Company Keay Nakae - Chardan Capita ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ (I.R.S. Employer Identification No.) 1010 Atlantic Avenue, Suite 102 Alameda, California 94501 (Address of principal executive offices) (Zip Cod ...

OncoCyte Corporation (NASDAQ:OCX) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Bob Yedid - IR, LifeSci Advisors William Annett - President and CEO Mitch Levine - CFO Lyndal Hesterberg - SVP, Research & Development Conference Call Participants Bill Quirk - Piper Jaffray Bruce Jackson - The Benchmark Company Casey Woodring - Janney Montgomery Scott Operator Good day and welcome to the OncoCyte Conference Call to discuss First Quarter 2019 Financial Results and Operating Highl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number 1-37648 OncoCyte Corporation (Exact name of registrant as specified in its charter) California 27-1041563 (State or other ...

OncoCyte Corporation (NASDAQ:OCX) Q4 2018 Results Earnings Conference Call April 1, 2019 4:30 AM ET Company Participants Bob Yedid - Investor Relations, Managing Director at LifeSci Advisors William Annett - President, Chief Executive Officer Mitch Levine - Chief Financial Officer Lyndal Hesterberg - Senior Vice President of Research & Development Conference Call Participants Bill Quirk - Piper Jaffray Paul Knight - Janney Montgomery Scott Bruce Jackson - The Benchmark Company Keay Nakae - Chardan Capital M ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number 1-37648 OncoCyte Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporat ...

OncoCyte Corporation Conference Call Summary Company Overview - **Company**: OncoCyte Corporation (NASDAQ: OCX) - **Focus**: Development of DetermaVu, a novel liquid biopsy lung cancer diagnostic test Key Industry Insights - **Lung Cancer Statistics**: Approximately 234,000 new cases and 154,000 deaths in the U.S. annually, highlighting the need for early detection [doc id='22'] - **Market Opportunity**: Estimated annual total addressable market of up to $4.7 billion in the U.S. for lung cancer diagnostics [doc id='25'] Core Findings from R&D Validation Study 1. **Test Performance**: DetermaVu demonstrated a sensitivity of 90% and specificity of 75% in a blinded study of 250 patient samples [doc id='9'][doc id='11] - **Confidence Intervals**: Sensitivity 95% CI: 82%-95%, Specificity 95% CI: 68%-81% [doc id='11'] - **Impact on Biopsies**: With 75% specificity, DetermaVu could eliminate up to 75% of unnecessary biopsies, potentially saving the healthcare system billions annually [doc id='11'] 2. **Innovative Approach**: Achieved results without including clinical data in the algorithm, a first in oncology diagnostics [doc id='9'][doc id='14'] - **Biological Basis**: Utilizes immune system responses to detect cancer, representing a breakthrough in cancer diagnostics [doc id='12'][doc id='19'] 3. **Future Applications**: The methodology has potential applications across other cancer types, expanding the scope of DetermaVu beyond lung cancer [doc id='15'][doc id='19'] Commercialization Plans - **Launch Timeline**: Targeting commercialization in the second half of 2019 [doc id='13'] - **Pricing Strategy**: Expected pricing between $3,000 to $4,000 per test, significantly lower than the average lung biopsy cost of $15,000 [doc id='51'] - **Sales Strategy**: Focused marketing to approximately 6,000 pulmonologists in the U.S. with a small, targeted sales force [doc id='52] Clinical Validation Steps - **Next Studies**: Plans for analytical validation, CLIA lab transfer validation, and clinical validation involving approximately 350 patients [doc id='20'][doc id='38] - **Expected Outcomes**: Anticipated results to fall within established confidence intervals, confirming the test's viability [doc id='38'] Additional Insights - **Complication Rates**: A recent JAMA study indicated a complication rate of 22%-24% from lung biopsies, underscoring the need for DetermaVu [doc id='24'] - **Payer Engagement**: Positive feedback from 10 public and commercial health plans covering 77 million lives, recognizing the unmet medical need addressed by DetermaVu [doc id='26] Conclusion - **Significant Breakthrough**: DetermaVu represents a potential standard in lung cancer screening and detection, with implications for broader cancer diagnostics [doc id='27] - **Future Updates**: OncoCyte plans to provide further updates on progress and financial results in upcoming calls [doc id='74]